Profile
| Role | Director |
|---|---|
| Notability | 20/100 |
Board memberships
- BridgeBio Oncology Therapeutics, Inc.
- BridgeBio Pharma, Inc.
Updated Jul 16, 2026
MCCORMICK FRANK has filed 2 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $8.36M.
| Role | Director |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-24 | BBIO | BridgeBio Pharma, Inc. | A — Grant or award | 4.0K | $0.00 | |
| 2025-09-05 | BBIO | BridgeBio Pharma, Inc. | S — Open-market sale | 74.0K | $53.16 | $3.93M |
| 2025-09-05 | BBIO | BridgeBio Pharma, Inc. | M — Option exercise | 74.0K | $11.92 | $882K |
| 2025-06-24 | BBIO | BridgeBio Pharma, Inc. | S — Open-market sale | 100.0K | $44.23 | $4.42M |
| 2025-06-20 | BBIO | BridgeBio Pharma, Inc. | A — Grant or award | 6.6K | $0.00 | |
| 2025-05-07 | BBIO | BridgeBio Pharma, Inc. | G — Bona-fide gift | 3.0K | $0.00 | |
| 2025-05-07 | BBIO | BridgeBio Pharma, Inc. | G — Bona-fide gift | 33.0K | $0.00 | |
| 2024-12-27 | BBIO | BridgeBio Pharma, Inc. | G — Bona-fide gift | 7.4K | $0.00 |
MCCORMICK FRANK is a corporate insider — currently tracked as Director of BridgeBio Pharma, Inc. (BBIO). InsiderAlpha tracks every SEC Form 4 filing in real time.
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($8.36M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live MCCORMICK FRANK profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.